Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT07226102

Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer

An E-Health Intervention for Fear of Progression in Women With Gynecologic or Breast Cancer

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
City of Hope Medical Center · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical trial tests feasibility, acceptability and how well a virtual mental health intervention, compared to enhanced usual care consisting of an educational intervention, works to address fear of progression for women with high risk or stage III-IV gynecologic or breast cancer. Worrying about cancer coming back or progression is natural for cancer patients. Many cancer patients face stress and uncertainty as they live longer and attend regular check-ups. A supportive program can help to develop skills to feel calmer and more resilient during uncertain times and better manage feelings of fear. The virtual mental health intervention may be a feasible, acceptable and effective may to address fear of progression for women with high risk or stage III-IV gynecologic or breast cancer.

Detailed description

PRIMARY OBJECTIVE: I. To determine the feasibility and acceptability of a blended e-health intervention to manage fear of progression (FOP) in patients with stage III or IV gynecologic (GYN) or breast cancer. SECONDARY OBJECTIVE: I. To determine the effects of the intervention on reducing fear of cancer progression (FOP) (primary outcome) and improving secondary outcomes of distress, anxiety, metacognitions, and mindfulness. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive access to the Day by Day platform that includes patient partner videos, testimonials, handouts and a community forum. Patients may optionally utilize these resources for 6 weeks. Patients attend online group sessions, over 60 minutes, for every other week for 3 sessions and complete online educational sessions on values clarification, managing worry and unhelpful thoughts, and skills practices to promote healthy coping on alternate weeks for 3 sessions. Patients complete a check in call, for 15-20 minutes, at week 3-4. Patients are asked to practice the skills including attention training, mindfulness, worry postponement, guided imagery and other practices from the intervention for 10-12 minutes, at least 6 days per week for and track their practice on the Day to Day platform for 6 weeks. Patients may be loaned a tablet if needed for 6 weeks. ARM II: Patients receive access to the Empower Hope platform. Patients attend online group sessions, over 60 minutes, for every other week for 3 sessions and complete online educational sessions on clinical trial participation, identifying reliable online information, healthy living on nutrition and activity/exercise and coping with fatigue on alternate weeks for 3 sessions. Patients complete a check in call, for 15-20 minutes, at week 3-4. Patients may be loaned a tablet if needed for 6 weeks. After completion of study intervention, patients are followed up at 12 weeks.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBehavioral InterventionAttend online group sessions
BEHAVIORALBehavioral InterventionComplete online educational sessions
BEHAVIORALBehavioral InterventionComplete check in call
BEHAVIORALBehavioral InterventionComplete daily skills practice
OTHEREducational InterventionReceive access to patient partner videos, testimonials, handouts and a community forum
OTHEREducational InterventionAttend online group sessions
OTHEREducational InterventionComplete online education sessions
OTHERInternet-Based InterventionReceive access to Day to Day platform
OTHERInternet-Based InterventionReceive access to the Empower Hope platform
OTHERInterviewAncillary studies
OTHERSurvey AdministrationAncillary studies
OTHERVirtual Technology InterventionReceive a tablet

Timeline

Start date
2026-07-16
Primary completion
2026-07-16
Completion
2026-07-16
First posted
2025-11-10
Last updated
2026-02-04

Locations

12 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT07226102. Inclusion in this directory is not an endorsement.